What is the best frontline therapy for patients with CLL and 17p deletion?

Current Hematologic Malignancy Reports

Volumn 6, Issue 1, 2011, Pages 36-46

  Badoux, Xavier C ^a   Keating, Michael J ^a   Wierda, William G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Alemtuzumab; Allogeneic stem cell transplantation; AlloSCT; Chronic lymphocytic leukemia; Combination therapies; del(17p); Frontline treatment; p53; Prognosis; TP53

Indexed keywords

ALEMTUZUMAB; BAFETINIB; BENDAMUSTINE; CAL 101; CHLORAMBUCIL; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLAVOPIRIDOL; FLUDARABINE; LENALIDOMIDE; METHYLPREDNISOLONE; MITOXANTRONE; OBATOCLAX; OBINUTUZUMAB; OBLIMERSEN; OFATUMUMAB; PCI 32765; PENTOSTATIN; PROTEIN P53; RITUXIMAB; ROSCOVITINE; TRU 016; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; DRUG MEGADOSE; GENE DELETION; GENE MUTATION; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79551499597     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0069-3     Document Type: Article

References (88)

1. CS Tam MJ Keating 2010 Chemoimmunotherapy of chronic lymphocytic leukemia Nat Rev Clin Oncol 7 521 532 1:CAS:528:DC%2BC3cXhtVyjsr%2FE 10.1038/nrclinonc.2010.101 20603650 This is a thorough review of chemoimmunotherapy in CLL.
2. M Hallek K Fischer G Fingerle-Rowson, et al. 2010 Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 1164 1174 1:CAS:528:DC%2BC3cXht1ersr%2FK 10.1016/S0140-6736(10)61381-5 20888994 This publication demonstrates the survival advantage gained by adding rituximab to fludarabine and cyclophosphamide in this important phase III study in untreated patients with CLL. In addition, the study confirms the inferior response and outcomes experienced by patients with 17p deletions.
3. CS Tam S O'Brien W Wierda, et al. 2008 Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 975 980 1:CAS:528:DC%2BD1cXpvVOks7c%3D 10.1182/blood-2008-02-140582 18411418 This article reports long-term results of the initial study of frontline FCR in patients with CLL.
4. M Isobe BS Emanuel D Givol, et al. 1986 Localization of gene for human p53 tumour antigen to band 17p13 Nature 320 84 85 1:CAS:528:DyaL28Xhs1Kms7o%3D 10.1038/320084a0 3456488
5. M Hollstein D Sidransky B Vogelstein, et al. 1991 p53 mutations in human cancers Science 253 49 53 1:CAS:528:DyaK3MXks1Gmurg%3D 10.1126/science.1905840 1905840
6. AJ Levine 1997 p53, the cellular gatekeeper for growth and division Cell 88 323 331 1:CAS:528:DyaK2sXhtFahtLg%3D 10.1016/S0092-8674(00)81871-1 9039259 (Pubitemid 27131374)
7. A Efeyan M Serrano 2007 p53: guardian of the genome and policeman of the oncogenes Cell cycle 6 1006 1010 1:CAS:528:DC%2BD2sXhtVSgu73K 17457049
8. T Seiler H Dohner S Stilgenbauer 2006 Risk stratification in chronic lymphocytic leukemia Semin Oncol 33 186 194 1:CAS:528:DC%2BD28XkvVahsLo%3D 10.1053/j.seminoncol.2006.01.017 16616065
9. S Bates AC Phillips PA Clark, et al. 1998 p14ARF links the tumour suppressors RB and p53 Nature 395 124 125 1:CAS:528:DyaK1cXmtVemsrY%3D 10.1038/25867 9744267 (Pubitemid 28425642)
10. DS Haines 1997 The mdm2 proto-oncogene Leuk Lymphoma 26 227 238 1:CAS:528:DyaK1cXnsFGktb4%3D 9322885
11. JC Marine G Lozano 2010 Mdm2-mediated ubiquitylation: p53 and beyond Cell death and differentiation 17 93 102 1:CAS:528:DC%2BD1MXhsFGnurvE 10.1038/cdd.2009.68 19498444
12. T Watanabe T Hotta A Ichikawa, et al. 1994 The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin Blood 84 3158 3165 1:CAS:528:DyaK2MXhslOlur4%3D 7949188
13. D Bixby L Kujawski S Wang, et al. 2008 The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis Cell cycle 7 971 979 1:CAS:528:DC%2BD1cXnvVSrsL8%3D 18414049
14. SL Harris AJ Levine 2005 The p53 pathway: positive and negative feedback loops Oncogene 24 2899 2908 1:CAS:528:DC%2BD2MXjtlehs7c%3D 10.1038/sj.onc. 1208615 15838523 (Pubitemid 40638098)
15. T Miyashita S Krajewski M Krajewska, et al. 1994 Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo Oncogene 9 1799 1805 1:CAS:528:DyaK2cXkslCqurc%3D 8183579
16. A Thomas S El Rouby JC Reed, et al. 1996 Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance Oncogene 12 1055 1062 1:CAS:528: DyaK28XhvVGqsrg%3D 8649796
17. JB Johnston P Daeninck L Verburg, et al. 1997 P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia Leuk Lymphoma 26 435 449 1:CAS:528:DyaK1MXisFahur4%3D 9389352
18. H Dohner S Stilgenbauer A Benner, et al. 2000 Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 1910 1916 1:CAS:528:DC%2BD3MXktlSlsQ%3D%3D 10.1056/NEJM200012283432602 11136261 (Pubitemid 32064784)
19. T Han H Ozer N Sadamori, et al. 1984 Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia N Engl J Med 310 288 292 1:STN:280:DyaL2c%2FptlCrtg%3D%3D 10.1056/NEJM198402023100504 6690952 (Pubitemid 14222042)
20. G Juliusson G Gahrton 1990 Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications Cancer Genet Cytogenet 45 143 160 1:STN:280:DyaK3c7pvFKrsA%3D%3D 10.1016/0165-4608(90)90079-P 2180558 (Pubitemid 20129138)
21. G Juliusson D Oscier G Juliusson, et al. 1991 Cytogenetic findings and survival in B-cell chronic lymphocytic leukemia. Second IWCCLL compilation of data on 662 patients Leukemia Lymphoma 5 21 25 10.3109/10428199109103374
22. DG Oscier J Stevens TJ Hamblin, et al. 1990 Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia Br J Haematol 76 352 358 1:STN:280:DyaK3M%2FosVamsQ%3D%3D 10.1111/j.1365-2141.1990.tb06367.x 2261345
23. S Pittman D Catovsky 1984 Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia Br J Haematol 58 649 660 1:STN:280:DyaL2M%2FpslKmtw%3D%3D 10.1111/j.1365-2141.1984.tb06112.x 6335048
24. CH Geisler P Philip BE Christensen, et al. 1997 In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients Leuk Res 21 1011 1023 1:STN:280:DyaK1c7gsFKkug%3D%3D 10.1016/S0145-2126(97)00095-7 9444933 (Pubitemid 28014204)
25. P Fenaux C Preudhomme JL Lai, et al. 1992 Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis Leukemia 6 246 250 1:STN:280:DyaK383mvFGiug%3D%3D 1588788
26. D Rossi M Cerri C Deambrogi, et al. 2009 The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness Clin Cancer Res. 15 995 1004 1:CAS:528:DC%2BD1MXht1Ontro%3D 10.1158/1078-0432.CCR-08-1630 19188171
27. T Zenz B Eichhorst R Busch, et al. 2010 TP53 mutation and survival in chronic lymphocytic leukemia J Clin Oncol 28 4473 4479 10.1200/JCO.2009.27.8762 20697090
28. T Butler JG Gribben 2010 Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia Blood reviews 24 135 141 1:CAS:528:DC%2BC3cXovFGjs70%3D 10.1016/j.blre.2010.03.004 20398985 This is an up-to-date review of the utility of molecular profiling in CLL, including the roles of prognostic factors in developing risk-stratified therapy.
29. M Dal-Bo F Bertoni F Forconi, et al. 2009 Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance J Translational Med 7 76 10.1186/1479-5876-7-76
30. CS Tam TD Shanafelt WG Wierda, et al. 2009 De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience Blood 114 957 964 1:CAS:528: DC%2BD1MXps1eit7s%3D 10.1182/blood-2009-03-210591 19414856 This study demonstrates that patients with 17p deletion identified at diagnosis may have heterogenous prognosis, which may be dissected according to other clinical predictors, including IGHV mutational status, Rai stage, and percentage of cells with 17p deletions by FISH.
31. T Zenz A Krober K Scherer, et al. 2008 Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up Blood 112 3322 3329 1:CAS:528:DC%2BD1cXht1OmurzF 10.1182/blood-2008-04-154070 18689542
32. OG Best AC Gardiner ZA Davis, et al. 2009 A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease Leukemia 23 212 214 1:CAS:528:DC%2BD1MXkvVejsw%3D%3D 10.1038/leu.2008.260 18818700
33. M Hallek BD Cheson D Catovsky, et al. 2008 Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 5446 5456 1:CAS:528: DC%2BD1cXnsVOktrk%3D 10.1182/blood-2007-06-093906 18216293 These updated guidelines on the management of CLL include indications for initial therapy.
34. H Dohner K Fischer M Bentz, et al. 1995 p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Blood 85 1580 1589 1:STN:280:DyaK2M7psFahtA%3D%3D 7888675
35. S el Rouby A Thomas D Costin, et al. 1993 p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression Blood 82 3452 3459 8241511
36. AR Pettitt AR Clarke JC Cawley, et al. 1999 Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms Br J Haematol 105 986 988 1:CAS:528:DyaK1MXksFylsLo%3D 10.1046/j.1365-2141.1999.01448.x 10554810 (Pubitemid 29309106)
37. AR Pettitt PD Sherrington JC Cawley 1999 The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia Br J Haematol 106 1049 1051 1:CAS:528:DyaK1MXmvVWht7g%3D 10.1046/j.1365-2141.1999.01649.x 10520012 (Pubitemid 29463023)
38. R Silber B Degar D Costin, et al. 1994 Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs Blood 84 3440 3446 1:CAS:528: DyaK2MXitV2htbs%3D 7949099
39. A Begleiter M Mowat LG Israels, et al. 1996 Chlorambucil in chronic lymphocytic leukemia: mechanism of action Leuk Lymphoma 23 187 201 1:CAS:528:DyaK1MXislCjt7w%3D 10.3109/10428199609054821 9031099
40. P Hillmen AB Skotnicki T Robak, et al. 2007 Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia J Clin Oncol 25 5616 5623 1:CAS:528:DC%2BD1cXmsFKltQ%3D%3D 10.1200/JCO.2007.12.9098 17984186
41. Oscier DG, Wade R, Orchard J, et al.: Prognostic Factors in the UK LRF CLL4 Trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:299.
42. D Catovsky S Richards E Matutes, et al. 2007 Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Lancet 370 230 239 1:CAS:528:DC%2BD2sXnvF2gs74%3D 10.1016/S0140-6736(07)61125-8 17658394 (Pubitemid 47069536)
43. IW Flinn DS Neuberg MR Grever, et al. 2007 Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997 J Clin Oncol 25 793 798 1:CAS:528:DC%2BD2sXjvVKmt7c%3D 10.1200/JCO.2006.08.0762 17283364 (Pubitemid 350002879)
44. S Stilgenbauer BF Eichhorst R Busch, et al. 2089 Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC)-Comprehensive Analysis of the CLL4 Trial of the GCLLSG ASH Annual Meeting Abstracts 2008 112
45. JC Byrd JG Gribben BL Peterson, et al. 2006 Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy J Clin Oncol 24 437 443 1:CAS:528:DC%2BD28XhsFSku7g%3D 10.1200/JCO.2005.03.1021 16344317 (Pubitemid 46655595)
46. NE Kay W Wu B Kabat, et al. 2010 Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia Cancer 116 2180 2187 1:CAS:528:DC%2BC3cXmsFSqt7s%3D 20187101
47. K Fischer P Cramer S Stilgenbauer, et al. 2009 Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract] ASH Annual Meeting Abstracts 114 205
48. F Bosch P Abrisqueta N Villamor, et al. 2009 Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia J Clin Oncol 27 4578 4584 1:CAS:528:DC%2BD1MXhtlCns77F 10.1200/JCO.2009.22.0442 19704063
49. S Faderl W Wierda S O'Brien, et al. 2010 Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years Leuk Res 34 284 288 1:CAS:528:DC%2BC3cXitVKltLc%3D 10.1016/j.leukres.2009.07.008 19646755
50. NE Kay SM Geyer TG Call, et al. 2007 Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Blood 109 405 411 1:CAS:528:DC%2BD2sXivVyktbY%3D 10.1182/blood-2006-07- 033274 17008537 (Pubitemid 46105933)
51. WG Wierda TJ Kipps J Durig, et al. 2009 Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial [abstract] ASH Annual Meeting Abstracts 114 207
52. MJ Keating I Flinn V Jain, et al. 2002 Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood 99 3554 3561 1:CAS:528:DC%2BD38XjvVGns7o%3D 10.1182/blood.V99.10.3554 11986207 (Pubitemid 34534522)
53. G Lozanski NA Heerema IW Flinn, et al. 2004 Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Blood 103 3278 3281 1:CAS:528:DC%2BD2cXjslKgsLs%3D 10.1182/blood-2003-10-3729 14726385 (Pubitemid 38525651)
54. NC Osuji I Del Giudice E Matutes, et al. 2005 The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53 Haematologica 90 1435 1436 1:CAS:528:DC%2BD2MXht1amtLrF 16219582
55. J Lundin E Kimby M Bjorkholm, et al. 2002 Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood 100 768 773 1:CAS:528:DC%2BD38XlvVCltrg%3D 10.1182/blood-2002-01-0159 12130484 (Pubitemid 34832599)
56. A Osterborg AS Fassas A Anagnostopoulos, et al. 1996 Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia Br J Haematol 93 151 153 1:STN:280:DyaK283gtVCntQ%3D%3D 10.1046/j.1365-2141.1996.450989.x 8611450 (Pubitemid 26132394)
57. Mauro FR, Cortelezzi A, Molica S, et al.: Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study. ASH Annual Meeting Abstracts 2008, 112:3167.
58. SA Parikh M Keating S O'Brien, et al. 2009 Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia ASH Annual Meeting Abstracts 114 208
59. MJ Dyer SM Kelsey HJ Mackay, et al. 1997 In vivo 'purging' of residual disease in CLL with Campath-1H Br J Haematol 97 669 672 1:STN:280: DyaK2szltFSntg%3D%3D 10.1046/j.1365-2141.1997.1062924.x 9207420
60. SM O'Brien HM Kantarjian DA Thomas, et al. 2003 Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia Cancer 98 2657 2663 10.1002/cncr.11871 14669286 (Pubitemid 37509530)
61. C Thieblemont F Bouafia E Hornez, et al. 2004 Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) Leuk Lymphoma 45 711 714 1:CAS:528:DC%2BD3sXpvV2ltr4%3D 10.1080/10428190310001615675 15160944 (Pubitemid 38256030)
62. Wierda WG, Kipps TJ, Keating MJ, et al.: Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2010
63. JC Byrd BL Peterson KR Rai, et al. 2009 Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901 Leuk Lymphoma 50 1589 1596 1:CAS:528:DC%2BD1MXhsVCks7bI 10.1080/10428190903150839 19863336
64. JD Hainsworth ER Vazquez DR Spigel, et al. 2008 Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network Cancer 112 1288 1295 1:CAS:528:DC%2BD1cXksFKju7k%3D 10.1002/cncr.23271 18189296 (Pubitemid 351429744)
65. TS Lin KA Donohue JC Byrd, et al. 2010 Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101 J Clin Oncol. 28 29 4500 4506 1:CAS:528:DC%2BC3cXhsVejt7zE 10.1200/JCO.2010.29. 7978 20697069
66. M Montillo A Tedeschi S Miqueleiz, et al. 2006 Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia J Clin Oncol 24 2337 2342 1:CAS:528:DC%2BD28XlvV2ksb0%3D 10.1200/JCO.2005.04.6037 16618945 (Pubitemid 46630666)
67. CD Schweighofer M Ritgen BF Eichhorst, et al. 2009 Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG) Br J Haematol 144 95 98 1:CAS:528:DC%2BD1MXhtleksb0%3D 10.1111/j.1365-2141.2008.07394.x 19016732
68. G Del Poeta MI Del Principe F Buccisano, et al. 2008 Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia Cancer. 112 119 128 10.1002/cncr.23144 17999417
69. PD Thornton E Matutes AG Bosanquet, et al. 2003 High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities Ann Hematol 82 759 765 1:CAS:528:DC%2BD3sXptleltLc%3D 10.1007/s00277-003-0710-5 14551737 (Pubitemid 38008843)
70. JE Castro DF James JD Sandoval-Sus, et al. 2009 Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia Leukemia 23 1779 1789 1:CAS:528:DC%2BD1MXht1GgtLvK 10.1038/leu.2009.133 19693094
71. DA Bowen TG Call GD Jenkins, et al. 2007 Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features Leuk Lymphoma 48 2412 2417 1:CAS:528:DC%2BD2sXhsVShtL3E 10.1080/10428190701724801 18067017 (Pubitemid 350253473)
72. Pettitt R, Matutes E, Dearden C, et al.: Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL. Haematologica 2009, 94[suppl.2]:abs. 0351.
73. Stilgenbauer S, Cymbalista F, Leblond V, et al. Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine - Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW. ASH Annual Meeting Abstracts 2010, 116(21):920.
74. CS Zent TG Call TD Shanafelt, et al. 2008 Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab Cancer 113 2110 2118 1:CAS:528:DC%2BD1cXht12lu77N 10.1002/cncr.23824 18759253
75. O Frankfurt E Hamilton S Duffey, et al. 2098 Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL-a Phase II Trial ASH Annual Meeting Abstracts 2008 112
76. Badoux X, Wierda WG, O'Brien SM, et al.: A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. J Clin Oncol 2010, 28:abstr 6508.
77. P Dreger P Corradini E Kimby, et al. 2007 Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus Leukemia 21 12 17 1:STN:280:DC%2BD28jivVyntw%3D%3D 10.1038/sj.leu.2404441 17109028 (Pubitemid 44921829)
78. P Dreger 2009 Allotransplantation for chronic lymphocytic leukemia Hematology 2009 602 609 10.1182/asheducation-2009.1.602
79. XC Badoux M Keating S O'Brien, et al. 2009 Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes ASH Annual Meeting Abstracts 114 1248
80. J Schetelig A van Biezen R Brand, et al. 2008 Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis J Clin Oncol 26 5094 5100 10.1200/JCO.2008.16.2982 18711173 The retrospective analysis of the EBMT registry data demonstrates the disease-free survival outcomes of patients with CLL after allogeneic stem cell transplantation. The survival of patients with 17p deletions is equivalent to those without deletions.
81. P Dreger H Dohner M Ritgen, et al. 2010 Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial Blood. 116 14 2438 2447 1:CAS:528:DC%2BC3cXhtlyqt7nI 10.1182/blood-2010-03-275420 20595516 These are results of a prospective trial of allogeneic stem cell transplantation in CLL, demonstrating the equivalent activity of transplantation (EFS) in patients with or without 17p deletion.
82. BA Christian MR Grever JC Byrd, et al. 2009 Flavopiridol in chronic lymphocytic leukemia: a concise review Clin Lymphoma Myeloma 9 Suppl 3 S179 185 1:CAS:528:DC%2BD1MXhtlantLbN 19778838
83. TS Lin AS Ruppert AJ Johnson, et al. 2009 Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease J Clin Oncol 27 6012 6018 1:CAS:528: DC%2BC3cXhtVWisLs%3D 10.1200/JCO.2009.22.6944 19826119
84. TS Lin KA Blum DB Fischer, et al. 2010 Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders J Clin Oncol 28 418 423 1:CAS:528:DC%2BC3cXivFartL4%3D 10.1200/JCO.2009.24.1570 20008633
85. Andritsos L, Furman R, Flinn IW, et al.: A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:3017.
86. T Robak K Jamroziak J Gora-Tybor, et al. 2010 Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study) J Clin Oncol 28 1863 1869 1:CAS:528:DC%2BC3cXmsFyitLc%3D 10.1200/JCO.2009.25.9630 20212251
87. F Bosch A Ferrer N Villamor, et al. 2008 Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication Clin Cancer Res 14 155 161 1:CAS:528:DC%2BD1cXoslCq 10.1158/1078-0432.CCR-07-1371 18172266 (Pubitemid 351377991)
88. BF Eichhorst R Busch S Stilgenbauer, et al. 2009 First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood 114 3382 3391 1:CAS:528:DC%2BD1MXhtlensb7N 10.1182/blood-2009-02-206185 19605849